Tolimidone and viable cells in HAMON cultures
Cell-based study · HAMON [1]
NECTIN4 siRNA-transfected HAMON cells were exposed to Tolimidone. The number of live cells was significantly increased compared with NECTIN4 siRNA-transfected, DMSO-treated cells.
| Endpoint | Reported result | Reference |
|---|---|---|
| number of viable cells | Reported result the number of live cells was significantly increased compared with NECTIN4 siRNA-transfected, DMSO-treated cells | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Method
- exposed to
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: NECTIN4 siRNA. Compound effect isolated by the comparison: NECTIN4-siRNA transfected DMSO-treated cells and NECTIN4-siRNA transfected MLR-1023-treated cells.
- Reported limits
- Not stated in the sentences used: schedule.
Methods and source locations
Compound reported in the paper: Tolimidone; Compound label in the paper: MLR-1023
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Effects of Src signaling reactivation in NECTIN4-knockdown angiosarcoma cells. (S83); Methods > Reagents (S104); Methods > siRNA transfection (S115); Methods > Cell proliferation assay (S124, S126); Figure 6 legend (S249, S252)
number of viable cells: number of viable cells; comparator: NECTIN4 siRNA-transfected, DMSO-treated cells — Results > Effects of Src signaling reactivation in NECTIN4-knockdown angiosarcoma cells. (S83); Figure 6 legend (S249)